Showing results (101-110 of 264) with videos related to
Sort By:
Pageof 27
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 15, 2011
The impact of a revised EQ-5D population scoring on preference-based utility scores in an inflammatory arthritis cohortRoisin Adams, Benjamin M Craig, Cathal D Walsh, et al.The Journal of Rheumatology|April 2, 2022
Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA ProjectsJames C Waddington, Orla Coleman, Philip J Mease, et al.Arthritis and Rheumatism|June 10, 2004
Increased synovial tissue NF-kappa B1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritisMaria J Benito, Eithne Murphy, Evelyn P Murphy, et al.Rheumatology International|May 2, 2020
Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritisPhilip J Mease, Iain B McInnes, Vibeke Strand, et al.The Journal of Rheumatology|March 3, 2019
Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or AdalimumabDésirée van der Heijde, Dafna D Gladman, Oliver FitzGerald, et al.Journal of the American Academy of Dermatology|May 23, 2006
Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapyTrevor Markham, Ronan Mullan, Lucy Golden-Mason, et al.Proteomics. Clinical Applications|September 3, 2015
Developing clinically relevant biomarkers in inflammatory arthritis: A multiplatform approach for serum candidate protein discoveryAngela McArdle, Aisha Qasim Butt, Agnes Szentpetery, et al.Arthritis Research & Therapy|December 20, 2024
Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysisDafna D Gladman, Peter Nash, Philip J Mease, et al.Annals of the Rheumatic Diseases|December 1, 2010
Development of a preliminary composite disease activity index in psoriatic arthritisAizad Mumtaz, Phil Gallagher, Brian Kirby, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 9, 2002
Activation of nuclear orphan receptor NURR1 transcription by NF-kappa B and cyclic adenosine 5'-monophosphate response element-binding protein in rheumatoid arthritis synovial tissueAlice N McEvoy, Eithne A Murphy, Tiia Ponnio, et al.Pageof 27